Visa Restrictions Limit Authorization To Practice Before Patent And Trademark Office
Client Alert | 1 min read | 02.21.06
There is no abuse of discretion in a Patent and Trademark Office denial of full registration to practice before the PTO to a nonimmigrant foreign individual, as full registration would have authorized that individual to do work in which she could not lawfully engage and would have been inconsistent with the terms of her visa, a Federal Circuit panel concludes in Catherine Lacavera v. Jon W. Dudas (No. 05-1204; February 6, 2006).
Lacavera, a Canadian citizen and nonimmigrant alien, began working in the United States as an attorney pursuant to a one year visa which permitted her only to prepare and prosecute patent applications at a New York law firm. Lacavera then successfully passed the patent bar examination but, because of legal restrictions imposed by her visa, was granted only limited recognition to practice before the PTO. Lacavera then challenged the PTO's decision to deny her full registration, initially before the PTO General Counsel and subsequently by filing suit in the United States District Court for the District of Columbia under the Administrative Procedure Act. Following denial of Lacavera's motion for summary judgment and grant of summary judgment in favor of the PTO, Lacavera appeals.
The CAFC panel affirms. 35 U.S.C. § 2(b)(2), the statute providing the PTO with authority to govern the conduct of proceedings before it and to govern the recognition and conduct of attorneys, is silent as to whether the PTO may consider visa restrictions in determining whether or not to grant recognition. However, the statute states that the PTO may require applicants to show that they are “possessed of the necessary qualifications to render to applicants” valuable service. It was reasonable for the PTO to enact regulations that limit an alien's ability to practice before it to those activities in which the alien may lawfully engage, and the PTO did not exceed its statutory authority in promulgating the regulations in question.
Insights
Client Alert | 7 min read | 06.26.26
Federal Roundup: Updates for PBMs and Medicare Advantage Organizations
In June 2026, federal regulators and lawmakers continued their efforts to improve drug affordability through targeted reforms. These recent developments will primarily impact pharmaceutical manufacturers, managed care organizations, and pharmacy benefit managers (PBM) serving Medicare Part D program members. PBMs, Medicare Advantage organizations, and Part D sponsors should monitor these changes in the interest of maintaining compliance and providing input on regulatory proposals that may influence their business operations or compensation structures in the future.
Client Alert | 6 min read | 06.26.26
Client Alert | 4 min read | 06.25.26
Twin Executive Orders Seek to Spur Quantum Leap in Technology and Cybersecurity
Client Alert | 7 min read | 06.24.26
